Prime Medicine, Inc. Common Stock (PRME)

Prime Medicine, Inc. Common Stock (PRME) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 26, 2026: market cap $666M; returns 1 day -1.6%, 1 week -5.7%, 1 year -32.3%.

Prime Medicine, Inc. (PRME) is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform. Their Prime Editing technology is a versatile, precise, and efficient gene editing technology designed to repair almost all types of genetic mutations across various tissues, organs, and cell types.

Groups PRME belongs to

• Biotechnology
• Life Sciences
• Healthcare
• Gene Therapy
• Precision Medicine
• Rare Diseases
• Clinical Stage Biotech
• Biopharmaceutical
• Clinical Stage
• Preclinical Development

PRME financial model: income statement, cash flow and balance sheet